Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
- PMID: 18385765
- DOI: 10.1038/gt.2008.54
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
Abstract
Recombinant vectors based on adeno-associated virus (AAV) have been shown to stably express many genes in vivo without mounting immune responses to vectors or transgenes. Thus, AAV vectors have rapidly become the reagents of choice for therapeutic gene transfer. Yet one of the first translations of AAV gene therapy into humans unexpectedly resulted in only short-term expression of the therapeutic gene accompanied by transient but significant toxicity. Immune responses to the vector capsid were held accountable for these results, confirming that a detailed understanding of the interaction of AAV vectors with the immune system is of great importance for the safety and success of gene therapy applications. Most humans display naturally acquired immunity to AAV; circumventing neutralizing antibodies and memory T-cell responses is challenging, but not impossible. This review will evaluate the strategies that have been proposed to overcome such responses and summarize recent findings about the mechanisms and circumstances that lead to the activation of innate and adaptive immune responses to AAV vector components.
Similar articles
-
Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.Gene Ther. 2006 Jan;13(1):29-39. doi: 10.1038/sj.gt.3302601. Gene Ther. 2006. PMID: 16136165
-
Receptor targeting of adeno-associated virus vectors.Gene Ther. 2003 Jul;10(14):1142-51. doi: 10.1038/sj.gt.3301976. Gene Ther. 2003. PMID: 12833123 Review.
-
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.Gene Ther. 2003 Jun;10(11):955-63. doi: 10.1038/sj.gt.3302037. Gene Ther. 2003. PMID: 12756416 Review.
-
Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.J Virol. 2001 Jan;75(1):269-77. doi: 10.1128/JVI.75.1.269-277.2001. J Virol. 2001. PMID: 11119597 Free PMC article.
-
Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.Gene Ther. 2004 Feb;11(3):233-40. doi: 10.1038/sj.gt.3302144. Gene Ther. 2004. PMID: 14737082
Cited by
-
Intravenous Administration Is an Effective and Safe Route for Cancer Gene Therapy Using the Bifidobacterium-Mediated Recombinant HSV-1 Thymidine Kinase and Ganciclovir.Int J Mol Sci. 2016 Jun 6;17(6):891. doi: 10.3390/ijms17060891. Int J Mol Sci. 2016. PMID: 27275821 Free PMC article.
-
CRISPR-Cas9‒Based Genomic Engineering in Keratinocytes: From Technology to Application.JID Innov. 2021 Dec 1;2(2):100082. doi: 10.1016/j.xjidi.2021.100082. eCollection 2022 Mar. JID Innov. 2021. PMID: 35146483 Free PMC article. Review.
-
Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins.J Immunol. 2009 May 15;182(10):6051-60. doi: 10.4049/jimmunol.0803965. J Immunol. 2009. PMID: 19414756 Free PMC article.
-
Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates.Hum Gene Ther Clin Dev. 2014 Sep;25(3):164-77. doi: 10.1089/humc.2013.239. Epub 2014 Aug 21. Hum Gene Ther Clin Dev. 2014. PMID: 25144894 Free PMC article.
-
Targeted gene therapy for the treatment of heart failure.Can J Cardiol. 2011 May-Jun;27(3):265-83. doi: 10.1016/j.cjca.2011.02.005. Can J Cardiol. 2011. PMID: 21601767 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical